Aavantgarde Bio

Developer of gene therapies using Adeno-Associated Viral vectors

placeMilano, Umbria, Italy calendar_todayFounded 2021 language aavantgarde.com

Social engagement

Social engagement: 7.4K social following, 10 posts in the last 12 months — below the industry typical range.

Investor mix

13 investors on record; lead investors include Atlas Venture, Forbion, Schroders Capital.

Investor typeCountShare
Venture capital969%
Angel & family office18%
Other / undisclosed323%

Recent activity

23 Jun 2026
Event
TechTalkXL: Cell & Gene Therapy
11 Jun 2026
Event
Webinar hosted by The Carroll Center for the Blind
11 Jun 2026
Event
6th Annual Clinical Trials at the Summit (CTS) 2026
Coming soon